VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4291)	3/10/1998 11:14:00 AM
From: squetch	of 9719

Peter & PB, PCYC is still an early stage company. I think this ASCO will put them on the map big time. That is my understanding of where the final PII Gd-Tex data will be presented. In the May 97 release for interim data on a PIb/II for 14 fourteen patients evaluated, 2 Complete responders and 9 partial responders, a 78% response rate, in brain cancer which had metastasized primarily from breast and lung cancer. What would 4 CR and 12 PR do for recognition?(just a hoped for lowball guess. I have another hope, but it has me in fear of the nice men in white suits coming to tell me it is nap time) They also have released data before the start of the PII where high dosage group survival was >363 days vs low dosage survival of 66 days. >>we don't know that it is 100% safe<<Agreed and I'm sure it won't be 100%.(:>) Grade 3 and 4 abnormalities in liver fx which have been seen late in the 10-day course of Gd-Tex therapy. It hadn't prevented any of the patients from completing therapy. We shall know more w/ the max tolerated dosage data in May. Cowen has PCYC earning $6.85 in '02. squetch

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next